Cytori Therapeutics CYTX today announced that a 40-patient,
multi-center investigator-sponsored and funded clinical study in Japan using
the Celution® System has been approved under the Ministry of Health, Labor and
Welfare (MHLW) Guidelines on Clinical Research Using Human Stem Cells.
The study will investigate the use of patients' own adipose-derived stem and
regenerative cells (ADRCs) processed by the Celution® System for peripheral
artery disease (PAD) or arteriosclerosis obliterans (AO). PAD or AO are common
circulatory problems in which narrowed arteries reduce blood flow to the
limbs. The principal investigator will be Toyoaki Murohara, M.D., Ph.D.,
Professor and Chairman, Department of Cardiology at the primary trial center,
Nagoya University Graduate School of Medicine. The trial will include two
additional Japanese sites.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in